Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

NCT ID: NCT01525875

Last Updated: 2021-03-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2015-03-31

Brief Summary

The purpose of this study is to evaluate the effectiveness of magnesium oxide supplements on the reversal of calcium deposits in the skin, and the yellow bumps and folds of skin in subjects with pseudoxanthoma elasticum (PXE). Magnesium oxide is a dietary supplement that has been shown in some research to reduce these calcium deposits. This study consists of two parts. The first part is a year-long, double-blind, placebo-controlled study. Part two is an open-label, year-long study. In Part 1, qualified subjects will be randomized to receive either magnesium oxide supplements or placebo, in a 1:1 ratio for the first 12 months. The starting dose will be 1000 mg daily, and depending on tolerability, doses may be decreased. Baseline evaluations will be comprised of: blood tests; clinical evaluations; skin biopsy; eye examination; bone density test; and photography of skin lesions. Subjects will be evaluated at week 2, week 6, month 3, and then every 3 months during the first year. Upon completion of the first year, barring any safety concerns, all subjects will be administered magnesium oxide supplements for up to one additional year. Subjects will undergo the same evaluations/ procedures every 3 months. We hypothesize that the magnesium oxide will cause a reduction in calcifications in the subject's soft tissue/skin. Funding Source - FDA OOPD.

Detailed Description

Pseudoxanthoma elasticum (PXE) is a systemic connective tissue disorder involving elastic fiber calcification and fragmentation with major clinical manifestations occurring in the cutaneous, ocular and cardiovascular systems.

Calcification of the elastic fibers leads to cracks in Bruch's membrane, an elastic tissue-containing membrane that separates the vascular choroid from the retinal pigment epithelium. These are known as angioid streaks and may be the only sign of the disease for years. Retinal hemorrhage and loss of vision are common. Calcification of the internal elastic lamina of arteries results in gastrointestinal bleeding, sometimes fatal in nature. Accelerated heart disease is an additional complication.

Cutaneous manifestations are characterized by the presence of yellow papules in a cobblestone pattern or plaques resembling "plucked chicken-skin" in flexural regions. Redundant folds of skin may develop in more advanced cases. The most frequent sites of cutaneous involvement include the neck, axillae, inguinal region, antecubital and popliteal fossae and the periumbilical area. Skin lesions provide an easy way of grading degree of calcification of elastic tissue.

A clinical study of 80 subjects with a variety of cutaneous soft tissue mineralization disorders had the affected areas injected locally with magnesium sulfate while also receiving oral magnesium lactate for 4 to 6 months. About 75% of these subjects showed a significant decrease or complete disappearance of calcification.

More recently, a knockout mouse model for PXE has linked a reversal in calcification to a diet high in magnesium. Mice were placed on diets that were either high or low in phosphate, high or low in magnesium, or on a controlled diet. The mice placed on the high magnesium diet did not show any evidence of connective tissue mineralization, while those on the other diets did show mineralization as characterized by calcification of the connective tissue capsule surrounding the vibrissae.

Based on this information and the research linking increased magnesium levels to decreased calcification, we plan to supplement the diets of PXE patients with magnesium oxide in order to show a reduction in elastic fiber calcification in the skin and to slow the progression of the disease.

Randomized subjects will be instructed to take study drug (active or placebo) for 12 months, then all subjects will receive active study drug for the following 12 months.

When ingested through foods, magnesium has not demonstrated any adverse effects. When obtained through supplements, however, excessive magnesium intake has been known to result in diarrhea as well as other gastrointestinal effects such as nausea, and abdominal cramping. Large pharmacological doses of magnesium have been associated with more serious side effects, such as metabolic alkalosis and hypokalemia with the repeated daily ingestion of 30g of magnesium oxide. Hypermagnesemia may result with excessive magnesium supplement ingestion, however, it has rarely been reported in individuals with normal renal function.

Study data will be analyzed using the Wilcoxon Rank Sum Test to compare changes in physician global assessment of skin lesions, evaluation of target lesions and assessment of biopsies between treatment and placebo groups. Assuming a negligible placebo response, we believe power analyses can be performed on our primary measure in 40 completed subjects as proposed in this study. Analyses will be based on intent-to-treat, with the last observation carried forward. Patients who withdraw for safety, lack of efficacy, and generally those without other documentation will in the absence of the requested 'final-visit evaluation' be assigned the highest (worst) score. A finding of significance based on the intent-to-treat analysis would be supplemented with an analysis of patients completing the trial without any protocol deviations.

Conditions

Pseudoxanthoma Elasticum

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Magnesium oxide

Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).

Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

Group Type: ACTIVE_COMPARATOR

Magnesium Oxide

Intervention Type: DRUG

Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).

Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

Placebo

Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

1000 mg (one 500 mg capsule two times daily) of placebo.

Interventions

Magnesium Oxide

Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).

Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).

Intervention Type: DRUG

Placebo

1000 mg (one 500 mg capsule two times daily) of placebo.

Intervention Type: DRUG

Other Intervention Names

magnesium oxide supplement; silica and/or cellulose

Eligibility Criteria

Inclusion Criteria

• Male or female subject at least 18 years of age
• If female, the subject is not pregnant or nursing
• If female of child bearing potential, the subject has a negative urine pregnancy test at the first visit, and agrees to use an approved method of contraception (hormonal contraceptives [birth control pills, implants [Norplant] or injections [DepoProvera]); intrauterine device (IUD); two forms of barrier methods [condoms and diaphragm]; or abstinence (no sexual activity) throughout the entire study
• Biopsy confirmed diagnosis of pseudoxanthoma elasticum (documenting some calcification of elastic fibers)
• Subject has a clinical disease severity grade of at least "1" (Poorly defined, barely visible macules) at screening.
• Normal kidney function tests

Exclusion Criteria

• Any subject who is pregnant or becomes pregnant during the study
• Subjects with a serum creatinine greater than 1.6 mg/dL
• Subjects with hypermagnesemia, hypokalemia, or idiopathic hypercalciuria
• Subjects with kidney disease or renal tubular defects (eg. Fanconi's syndrome), or on dialysis
• Subjects with hypothyroidism or hypoparathyroidism or primary hyperparathyroidism
• Subjects with acute gout
• Subjects with malabsorption, or osteomalacia
• Subjects on diuretics, magnesium containing antacids, or anabolic steroids
• Subjects with Cushing's syndrome
• Subjects receiving lithium and those with significant psychiatric disorders that would likely interfere with participation in this study
• Subjects taking anti-seizures medications and anti-arrhythmics medications
• Subjects on tetracycline or metronidazole and ace inhibitors
• Subjects taking cyclosporine or calcineurin inhibitors

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mark Lebwohl

OTHER

Sponsor Role: lead

Responsible Party

Mark Lebwohl

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Mark Lebwohl, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Countries

United States

References

Lebwohl M, Neldner K, Pope FM, De Paepe A, Christiano AM, Boyd CD, Uitto J, McKusick VA. Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol. 1994 Jan;30(1):103-7. doi: 10.1016/s0190-9622(08)81894-4. No abstract available.

Reference Type: BACKGROUND

PMID: 8277008 (View on PubMed)

Neldner KH. Pseudoxanthoma elasticum. Clin Dermatol. 1988 Jan-Mar;6(1):1-159. doi: 10.1016/0738-081x(88)90003-x. No abstract available.

Reference Type: BACKGROUND

PMID: 3359381 (View on PubMed)

Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol. 1982 Mar-Apr;26(5):235-46. doi: 10.1016/0039-6257(82)90158-8.

Reference Type: BACKGROUND

PMID: 7046115 (View on PubMed)

Renie WA, Pyeritz RE, Combs J, Fine SL. Pseudoxanthoma elasticum: high calcium intake in early life correlates with severity. Am J Med Genet. 1984 Oct;19(2):235-44. doi: 10.1002/ajmg.1320190205.

Reference Type: BACKGROUND

PMID: 6507474 (View on PubMed)

Martinez-Hernandez A, Huffer WE, Neldner K, Gordon S, Reeve EB. Resolution and repair of elastic tissue calcification in pseudoxanthoma elasticum. Arch Pathol Lab Med. 1978 Jun;102(6):303-5.

Reference Type: BACKGROUND

PMID: 580723 (View on PubMed)

Sapadin AN, Lebwohl MG, Teich SA, Phelps RG, DiCostanzo D, Cohen SR. Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysis. J Am Acad Dermatol. 1998 Aug;39(2 Pt 2):338-44. doi: 10.1016/s0190-9622(98)70385-8.

Reference Type: BACKGROUND

PMID: 9703148 (View on PubMed)

Sherer DW, Singer G, Uribarri J, Phelps RG, Sapadin AN, Freund KB, Yanuzzi L, Fuchs W, Lebwohl M. Oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol. 2005 Oct;53(4):610-5. doi: 10.1016/j.jaad.2004.11.066.

Reference Type: BACKGROUND

PMID: 16198780 (View on PubMed)

Blum R, Phelps R, Fuchs W, Lebwohl M. Oral Phosphate Binders in the Treatment of Pseudoxanthoma Elasticum. 64th Annual Meeting American Academy of Dermatology March 3-7, 2006, San Francisco, CA. Manuscript in press J Amer Acad Dermatol 2011

Reference Type: BACKGROUND

Steidl L, Ditmar R. Treatment of soft tissue calcifications with magnesium. Acta Univ Palacki Olomuc Fac Med. 1991;130:273-87.

Reference Type: BACKGROUND

PMID: 1838878 (View on PubMed)

LaRusso J, Li Q, Jiang Q, Uitto J. Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)). J Invest Dermatol. 2009 Jun;129(6):1388-94. doi: 10.1038/jid.2008.391. Epub 2009 Jan 1.

Reference Type: BACKGROUND

PMID: 19122649 (View on PubMed)

Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984 Jul;108(1):188-93. doi: 10.1016/0002-8703(84)90572-6. No abstract available.

Reference Type: BACKGROUND

PMID: 6375330 (View on PubMed)

Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr. 1987 Feb;45(2):469-75. doi: 10.1093/ajcn/45.2.469.

Reference Type: BACKGROUND

PMID: 3812346 (View on PubMed)

Paolisso G, Passariello N, Pizza G, Marrazzo G, Giunta R, Sgambato S, Varricchio M, D'Onofrio F. Dietary magnesium supplements improve B-cell response to glucose and arginine in elderly non-insulin dependent diabetic subjects. Acta Endocrinol (Copenh). 1989 Jul;121(1):16-20. doi: 10.1530/acta.0.1210016.

Reference Type: BACKGROUND

PMID: 2662695 (View on PubMed)

Rude RK, Singer FR. Magnesium deficiency and excess. Annu Rev Med. 1981;32:245-59. doi: 10.1146/annurev.me.32.020181.001333. No abstract available.

Reference Type: BACKGROUND

PMID: 7013665 (View on PubMed)

Dietary Reference Intakes for Calcium, Magnesium, Vitamin D and Flouride. IOM Institute of Medicine. 1997 Washington, DC: National Academy Press.

Reference Type: BACKGROUND

Bashir Y, Sneddon JF, Staunton HA, Haywood GA, Simpson IA, McKenna WJ, Camm AJ. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1993 Nov 15;72(15):1156-62. doi: 10.1016/0002-9149(93)90986-m.

Reference Type: BACKGROUND

PMID: 8237806 (View on PubMed)

Urakabe S, Nakata K, Ando A, Orita Y, Abe H. Hypokalemia and metabolic alkalosis resulting from overuse of magnesium oxide. Jpn Circ J. 1975 Oct;39(10):1135-7. doi: 10.1253/jcj.39.1135.

Reference Type: BACKGROUND

PMID: 1195509 (View on PubMed)

Other Identifiers

FD-R-0003903

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

GCO 09-1157

Identifier Type: -

Identifier Source: org_study_id